Daily Roundup

AMX.ASX AIZ.ASX SKO.ASX TLX.ASX CU6.ASX

A Busy Day in the Markets: Aerometrex Secures Contracts, Air New Zealand Suspends Guidance, and More

Aerometrex has been busy securing a series of new government contracts across federal, state, and local departments. The Australian-owned and operated company has landed deals worth around $2.5 million over the next 3 years, covering both its MetroMap subscription and LiDAR project revenue. Aerometrex's status as a domestic provider with proven delivery capabilities has been a key factor in these successful tenders, as the government looks to support local industry and sovereign capability.

Over in the aviation sector, Air New Zealand has been forced to suspend its FY2026 earnings guidance due to unprecedented volatility in global jet fuel markets. The conflict in the Middle East has sent fuel prices skyrocketing, from around $85-$90 per barrel to as high as $150-$200 per barrel. While the airline is hedged against Brent crude, it remains exposed to the widening crack spread, which has more than quintupled. Air New Zealand has already implemented some fare adjustments and is pursuing cost-cutting initiatives, but further network and schedule changes may be necessary if the fuel crisis persists.

Elsewhere, Serko, the leading Australasian travel and expense management solutions provider, has provided an upbeat FY26 trading update as part of its Investor Day. The company highlighted strong financial performance, with revenue and profitability exceeding market expectations. Serko is focused on driving future growth through product innovation, international expansion, and sustainability initiatives - and it's guiding for revenue of $250-$270 million and an EBITDA margin of 20-25% in the coming fiscal year.

In the pharmaceutical space, Telix Pharmaceuticals has reported positive results from Part 1 of its ProstACT Global Phase 3 study, evaluating its novel radiopharmaceutical TLX591-Tx in metastatic castration-resistant prostate cancer. The study demonstrated an acceptable safety and tolerability profile, with no new safety signals observed. Telix plans to present these findings to the FDA as it seeks to progress the study into its randomized expansion phase.

And finally, Clarity Pharmaceuticals has achieved its target enrollment for the Phase 3 AMPLIFY trial, which is investigating the diagnostic performance of its 64Cu-SAR-bisPSMA PET/CT imaging agent in detecting prostate cancer recurrence. The study results will support Clarity's FDA approval application for this new diagnostic imaging tool.

All in all, it's been a busy day for the ASX, with a diverse range of companies making key announcements across the healthcare, aviation, and technology sectors. Investors will be closely watching these developments as they assess the growth prospects and challenges facing these dynamic Australian businesses.